PGR and neoplasm: In the ribociclib group, ER+/PR− tumours had worse mPFS compared with ER+/PR+ tumours (44 months vs. 10.1 months, respectively, p = 0.0014) (Figure 3E) and borderline non-significance for mOS (54.8 months vs. 34.3 months, respectively, p = 0.073) (Figure 3F).